BCMA/TNFRSF17 Rekombinanter Antikörper
BCMA/TNFRSF17 Rekombinant Antikörper für FC
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human
Anwendung
FC
Konjugation
Unkonjugiert
CloneNo.
241731A11
Kat-Nr. : 98215-1-PBS
Synonyme
Geprüfte Anwendungen
Produktinformation
98215-1-PBS bindet in FC BCMA/TNFRSF17 und zeigt Reaktivität mit human
| Getestete Reaktivität | human |
| Wirt / Isotyp | Kaninchen / IgG |
| Klonalität | Rekombinant |
| Typ | Antikörper |
| Immunogen | Rekombinantes Protein |
| Vollständiger Name | tumor necrosis factor receptor superfamily, member 17 |
| Berechnetes Molekulargewicht | 184 aa, 20 kDa |
| GenBank-Zugangsnummer | BC058291 |
| Gene symbol | TNFRSF17 |
| Gene ID (NCBI) | 608 |
| Konjugation | Unkonjugiert |
| Form | Liquid |
| Reinigungsmethode | Protein A purfication |
| Lagerungspuffer | PBS only |
| Lagerungsbedingungen | Store at -80°C. |
Hintergrundinformationen
BCMA (B cell maturation antigen), also known as TNFRSF17, is 20.2-kDa type III transmembrane glycoprotein and is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes and plasma cells, which may be important for B cell development and autoimmune response (PMID: 32943087; 9846698). BCMA has two agonist ligands: a proliferation-inducing ligand (APRIL) and BAFF. When BCMA binds to APRIL, it transmits signals of cell survival and proliferation (PMID: 27127303); when BCMA binds to BAFF, it mediates the activation of NF-kappaB and MAPK8/JNK (PMID: 36140254). It has been found that the overexpression and activation of BCMA are associated with multiple myeloma (MM) in preclinical models and humans, supporting its potential utility as a therapeutic target for MM (PMID: 32055000; 32943087).



